Failure of copolymer I to inhibit the human T-cell response to myelin basic protein.
In clinical trials, copolymer I (Cop 1) appears to reduce the number of exacerbations in early relapsing-remitting multiple sclerosis. The mechanism of this effect is uncertain, but Cop 1 also reduces the severity of experimental allergic encephalomyelitis and inhibits the response of murine myelin basic protein (MBP)-specific T cells. We tested MBP-specific T-cell lines and clones from four subjects to determine whether Cop 1 also limits the human response to MBP. We found no inhibition by Cop 1 of the human T-cell response to MBP.
Burns
J
J
Neurology Service, Veterans Affairs Medical Center, Salt Lake City, UT 84148.
Littlefield
K
K
D002455:Cell Division / Q000187:drug effects; D002460:Cell Line; D004305:Dose-Response Relationship, Drug; D006801:Humans; D004676:Myelin Basic Protein / Q000494:pharmacology*; D009994:Osmolar Concentration; D010455:Peptides / Q000494:pharmacology*; D013601:T-Lymphocytes / Q000166:cytology / Q000187:drug effects*
D004676:Myelin Basic Protein; D010455:Peptides; C021759:(T,G)-A-L